| Description | Samalizumab (ALXN 6000), a humanized monoclonal antibody, selectively targets and inhibits the interaction between CD200 and its receptor (CD200R). This compound is utilized in the research of multiple myeloma and B-cell chronic lymphocytic leukemia [1]. |
| In vitro | Samalizumab 经过精确设计，含有 Ig G2/G4 恒定区以最大化降低效应子功能并维护免疫细胞亚群的完整性。该化合物是重组人源化抗CD200单克隆抗体，专门针对免疫检查点CD200进行特异性结合，阻断其受体的参与及信号传导。Samalizumab拮抗CD200引起的免疫抑制，激活抗肿瘤免疫反应[1]。 |
| Synonyms | ALXN 6000 |
| molecular weight | N/A |
| CAS | 1073059-33-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |